AR and posterior cortical atrophy: Collectively, these findings reveal that BM-PCa, and particularly aggressive AR-negative cells which would be resistant to androgen deprivation therapy, could be targeted by the combined suppression of ROS and glutathione metabolism as a novel therapeutic strategy for treating BM-PCa patients.